BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 37695584)

  • 1. Biochemical Recurrence and Risk of Mortality Following Radiotherapy or Radical Prostatectomy.
    Falagario UG; Abbadi A; Remmers S; Björnebo L; Bogdanovic D; Martini A; Valdman A; Carrieri G; Menon M; Akre O; Eklund M; Nordström T; Grönberg H; Lantz A; Wiklund P
    JAMA Netw Open; 2023 Sep; 6(9):e2332900. PubMed ID: 37695584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. European Association of Urology Biochemical Recurrence Risk Classification as a Decision Tool for Salvage Radiotherapy-A Multicenter Study.
    Preisser F; Abrams-Pompe RS; Stelwagen PJ; Böhmer D; Zattoni F; Magli A; Rivas JG; Dilme RV; Sepulcri M; Eguibar A; Heidegger I; Arnold C; Fankhauser CD; Chun FK; van der Poel H; Gandaglia G; Wiegel T; van den Bergh RCN; Tilki D;
    Eur Urol; 2024 Feb; 85(2):164-170. PubMed ID: 37355358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.
    Brockman JA; Alanee S; Vickers AJ; Scardino PT; Wood DP; Kibel AS; Lin DW; Bianco FJ; Rabah DM; Klein EA; Ciezki JP; Gao T; Kattan MW; Stephenson AJ
    Eur Urol; 2015 Jun; 67(6):1160-1167. PubMed ID: 25301759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term cancer control outcomes in patients with clinically high-risk prostate cancer treated with robot-assisted radical prostatectomy: results from a multi-institutional study of 1100 patients.
    Abdollah F; Sood A; Sammon JD; Hsu L; Beyer B; Moschini M; Gandaglia G; Rogers CG; Haese A; Montorsi F; Graefen M; Briganti A; Menon M
    Eur Urol; 2015 Sep; 68(3):497-505. PubMed ID: 26119559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Event-free survival after radical prostatectomy according to prostate-specific membrane antigen-positron emission tomography and European Association of Urology biochemical recurrence risk groups.
    Roberts MJ; Chatfield MD; Hruby G; Nandurkar R; Roach P; Watts JA; Cusick T; Kneebone A; Eade T; Ho B; Nguyen A; Tang C; McCarthy M; Francis R; Stricker P; Emmett L
    BJU Int; 2022 Nov; 130 Suppl 3(Suppl 3):32-39. PubMed ID: 35488182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of the European association of urology biochemical recurrence risk groups after radical prostatectomy in an Asian cohort and suggestions for refinement.
    Pak S; Lee DE; You D; Jeong IG; Joung JY; Lee KH; Hong JH; Kim CS; Ahn H
    Urol Oncol; 2021 May; 39(5):298.e1-298.e6. PubMed ID: 33579626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are biochemical recurrence outcomes similar after radical prostatectomy and radiation therapy? Analysis of prostate cancer-specific mortality by nomogram-predicted risks of biochemical recurrence.
    Lee BH; Kibel AS; Ciezki JP; Klein EA; Reddy CA; Yu C; Kattan MW; Stephenson AJ
    Eur Urol; 2015 Feb; 67(2):204-9. PubMed ID: 25294696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of Risk Models in Decision Making After Radical Prostatectomy: Lessons from a Natural History Cohort of Intermediate- and High-Risk Men.
    Ross AE; Yousefi K; Davicioni E; Ghadessi M; Johnson MH; Sundi D; Tosoian JJ; Han M; Humphreys EB; Partin AW; Walsh PC; Trock BJ; Schaeffer EM
    Eur Urol; 2016 Mar; 69(3):496-504. PubMed ID: 25922274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer.
    Xiang M; Ma TM; Savjani R; Pollom EL; Karnes RJ; Grogan T; Wong JK; Motterle G; Tosoian JJ; Trock BJ; Klein EA; Stish BJ; Dess RT; Spratt DE; Pilar A; Reddy C; Levin-Epstein R; Wedde TB; Lilleby WA; Fiano R; Merrick GS; Stock RG; Demanes DJ; Moran BJ; Huland H; Tran PT; Martin S; Martinez-Monge R; Krauss DJ; Abu-Isa EI; Alam R; Schwen Z; Pisansky TM; Choo CR; Song DY; Greco S; Deville C; McNutt T; DeWeese TL; Ross AE; Ciezki JP; Boutros PC; Nickols NG; Bhat P; Shabsovich D; Juarez JE; Chong N; Kupelian PA; Rettig MB; Zaorsky NG; Berlin A; Tward JD; Davis BJ; Reiter RE; Steinberg ML; Elashoff D; Horwitz EM; Tendulkar RD; Tilki D; Czernin J; Gafita A; Romero T; Calais J; Kishan AU
    JAMA Netw Open; 2021 Dec; 4(12):e2138550. PubMed ID: 34902034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancer-specific Mortality: Competition Between Age and Time to Biochemical Failure.
    Jackson WC; Suresh K; Tumati V; Dess RT; Soni PD; Zhao SG; Zumsteg ZS; Hannan R; Hollenbeck BK; George A; Kaffenberger SD; Salami SS; Hearn JWD; Morgan TM; Mehra R; Schipper M; Feng FY; Desai NB; Spratt DE
    Eur Urol Oncol; 2018 Sep; 1(4):276-282. PubMed ID: 31100248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. European association of urology risk stratification predicts outcome in patients receiving PSMA-PET-planned salvage radiotherapy for biochemical recurrence following radical prostatectomy.
    Scharl S; Zamboglou C; Strouthos I; Farolfi A; Serani F; Koerber SA; Debus J; Peeken JC; Vogel MME; Kroeze SGC; Guckenberger M; Krafcsik M; Hruby G; Emmett L; Schmidt-Hegemann NS; Trapp C; Spohn SKB; Henkenberens C; Mayer B; Shelan M; Aebersold DM; Thamm R; Wiegel T
    Radiother Oncol; 2024 May; 194():110215. PubMed ID: 38458259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk Stratification of Patients Candidate to Radical Prostatectomy Based on Clinical and Multiparametric Magnetic Resonance Imaging Parameters: Development and External Validation of Novel Risk Groups.
    Mazzone E; Gandaglia G; Ploussard G; Marra G; Valerio M; Campi R; Mari A; Minervini A; Serni S; Moschini M; Marquis A; Beauval JB; van den Bergh R; Rahota RG; Soeterik T; Roumiguiè M; Afferi L; Zhuang J; Guo H; Mattei A; Gontero P; Cucchiara V; Stabile A; Fossati N; Montorsi F; Briganti A
    Eur Urol; 2022 Feb; 81(2):193-203. PubMed ID: 34399996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment.
    Loeb S; Folkvaljon Y; Robinson D; Schlomm T; Garmo H; Stattin P
    Eur Urol; 2016 Nov; 70(5):824-828. PubMed ID: 26743040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review.
    Van den Broeck T; van den Bergh RCN; Arfi N; Gross T; Moris L; Briers E; Cumberbatch M; De Santis M; Tilki D; Fanti S; Fossati N; Gillessen S; Grummet JP; Henry AM; Lardas M; Liew M; Rouvière O; Pecanka J; Mason MD; Schoots IG; van Der Kwast TH; van Der Poel HG; Wiegel T; Willemse PM; Yuan Y; Lam TB; Cornford P; Mottet N
    Eur Urol; 2019 Jun; 75(6):967-987. PubMed ID: 30342843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.
    Fossati N; Karnes RJ; Cozzarini C; Fiorino C; Gandaglia G; Joniau S; Boorjian SA; Goldner G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T; Briganti A
    Eur Urol; 2016 Apr; 69(4):728-733. PubMed ID: 26497924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salvage Radical Prostatectomy for Recurrent Prostate Cancer Following First-line Nonsurgical Treatment: Validation of the European Association of Urology Criteria in a Large, Multicenter, Contemporary Cohort.
    Calleris G; Marra G; Benfant N; Rajwa P; Ahmed M; Abreu A; Cacciamani G; Ghoreifi A; Ribeiro L; Westhofen T; Tourinho-Barbosa R; Raskin Y; Veerman H; Albisinni S; Smith JA; Rouprêt M; Oderda M; Massari E; Persad R; Van Der Poel H; Joniau S; Sanchez-Salas R; Kretschmer A; Cathcart P; Gill I; Karnes RJ; Tilki D; Shariat SF; Touijer K; Gontero P
    Eur Urol Focus; 2023 Jul; 9(4):645-649. PubMed ID: 36682962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. External Validation of the European Association of Urology Biochemical Recurrence Risk Groups to Predict Metastasis and Mortality After Radical Prostatectomy in a European Cohort.
    Tilki D; Preisser F; Graefen M; Huland H; Pompe RS
    Eur Urol; 2019 Jun; 75(6):896-900. PubMed ID: 30955970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison of the Biochemical Recurrence risk between Radical Prostatectomy and Brachytherapy in the treatment of low- and intermediate-risk prostate cancer].
    Martínez PF; Belisle DF; Cristallo C; Tobía I; Damia O; Villamil W; Giudice CR
    Arch Esp Urol; 2015 Oct; 68(8):655-60. PubMed ID: 26437328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvage radiotherapy for biochemical recurrence after radical prostatectomy: does the outcome depend on the prostate cancer characteristics?
    Viani GA; Hamamura AC; Correa AC; de Arruda FT
    Int Braz J Urol; 2019; 45(2):237-245. PubMed ID: 30676298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positive surgical margins and biochemical recurrence following minimally-invasive radical prostatectomy - An analysis of outcomes from a UK tertiary referral centre.
    Sachdeva A; Veeratterapillay R; Voysey A; Kelly K; Johnson MI; Aning J; Soomro NA
    BMC Urol; 2017 Oct; 17(1):91. PubMed ID: 28969608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.